– TGD001 was well tolerated with no dose-limiting toxicities across all dose cohorts, exhibiting potent thrombolytic activity – New preclinical data demonstrate efficacy across multiple in vivo models of thrombosis – TargED will rapidly advance...
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and...
TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced that first clinical and new preclinical data on its lead investigational thrombolytic fusion protein,...
Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical activity, and robust biomarker responses Data provides strong validation for the advancement of CIT-013 into Phase IIa studies Oss, Netherlands – 27 October...
Quickborn, Germany and Eindhoven, Netherlands – September 24, 2025 – Mammotome, a globally recognized leader in breast care, and Sirius Medical, a pioneer of Surgical Marker Navigation, are proud to announce an exclusive distribution agreement for the...
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company pioneering a transformative approach to...
